U.S. Representatives Who Sided With Big Pharma in Medicare Lobbying Fight Received 82% More Industry Campaign Contributions
July 11, 2016 — The report sheds light on the role of money in politics in the debate in Congress surrounding the Centers for Medicare & Medicaid Services’ proposed Medicare Part B demonstration project. The project is intended to lower costs to taxpayers and patients by decreasing doctors’ incentive to administer the most expensive drugs provided under Medicare Part B. One of the report’s key findings is that U.S. Representatives who sided with the pharmaceutical industry against the reforms received 82 percent more in campaign contributions for the 2016 election cycle than members who did not side with the industry.